Cancer clinical trials in the region Pays de la Loire

413 currently recruiting clinical trials
Region Pays de la Loire

Phase 3 Lung cancer #NCT05078047
Required disease stage
Locally Advanced Metastatic
Required previous treatments at advanced or metastatic stage
Immunotherapy
25 recruiting sites
UNICANCER
Phase 3 Pancreas cancer #NCT00268411
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Chemotherapy Radiotherapy
Excluded previous treatments at advanced or metastatic stage
Chemotherapy Radiotherapy
14 recruiting sites
GERCOR - Groupe Coopératif Multidisciplinaire d'Oncologie
Phase 3 Breast cancer #NCT06393374
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Localized Locally Advanced
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Surgery Immunotherapy Chemotherapy
Required previous treatments at advanced or metastatic stage
Surgery Immunotherapy Chemotherapy
Excluded genetic anomalies
BRCA 1/2
Excluded previous treatments at localized stage
Systemic Treatment-Naive Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Antibody Drug Conjugates (ADC)
17 recruiting sites
Merck Sharp & Dohme LLC
Phase 3 Prostate cancer #NCT06625970
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized
Required PSMA PET Scan statuses
PSMA PET Negative
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Surgery Radiotherapy Internal Vectorised Radiotherapy (IVR)
11 recruiting sites
UNICANCER
Phase 3 Lymphoma #NCT06522737
Required histologic types
T cell lymphoma
Required histologic sub types
Peripheral T cell lymphoma
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments
Chemotherapy
Excluded previous treatments
Systemic Treatment-Naive
11 recruiting sites
SecuraBio
Phase 3 Rectal cancer #NCT06762405
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized Locally Advanced
Required genetic anomalies
MSI/dMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Immunotherapy Chemotherapy Radiotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Chemotherapy Radiotherapy
10 recruiting sites
CHU Dijon
Phase 3 Kidney cancer #NCT05078047
Required disease stage
Locally Advanced Metastatic
Required previous treatments at advanced or metastatic stage
Immunotherapy
25 recruiting sites
UNICANCER
Phase 2 / Phase 3 Bladder / Urinary Tract / Urethral cancer #NCT07129993 #2024-516906-47-00
Required histologic types
Invasive bladder cancer Upper excretory tract cancer Urethral cancer
Required histologic sub types
Urothelial carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Immunotherapy Antibody Drug Conjugates (ADC)
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
15 recruiting sites
Daiichi Sankyo
Phase 2 / Phase 3 Endometrial cancer #NCT03651206 #2024-516782-36-00
Required histologic sub types
Carcinosarcoma
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at localized stage
Chemotherapy
Required previous treatments at advanced or metastatic stage
Chemotherapy
Excluded previous treatments at localized stage
Systemic Treatment-Naive Immunotherapy Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Immunotherapy Targeted therapy
16 recruiting sites
ARCAGY/ GINECO GROUP
Phase 2 / Phase 3 Multiple myeloma #NCT07095452 #2025-520897-21-00
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
Required IMWG cytogenetic prognoses
High risk
15 recruiting sites
Abbvie